Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical Cancer: early-phase trial registry
73 of 151 indexed Cervical Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #76 of 28,707 conditions by registered trial count.
151 US clinical trials · 73 currently recruiting · #76 of 28,707 conditions by registered trial count
Cervical Cancer: 151 US clinical trials tracked, 73 recruiting.
Cervical Cancer is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 78 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition cervical-cancer
OPEN 73 | RECR 48% | LATE 8 | EARLY 78 | RANK #76 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Chronic Graft Versus Host Disease (48% recruiting · 31 trials)
Cervical Cancer lists 73 open slots (48% of 151 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cervical Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cervical Cancer is recruiting above its size-band peers.
73 of 151 indexed trials (48.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cervical Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 11 of 151 trials (7.3%). 101 distinct sponsors appear on at least one study for this condition label.
-
Typical Cervical Cancer enrolment sits around 100 participants.
Median target enrolment is 100 among the 145 trials that report a genuine target (sentinel values excluded). 72 of those (49.7%) plan for fewer than 100 participants.
-
Cervical Cancer research is mostly interventional.
131 interventional and 20 observational studies make up this index (86.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
151 total, page 2 of 4
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
University of Oklahoma
NCT05512208
Image-Guided Gynecologic Brachytherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02993900
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Memorial Sloan Kettering Cancer Center
NCT06925724
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
Medical College of Wisconsin
NCT07227077
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med
NCT05283330
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen
NCT06157151
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
NCT04038619
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
M.D. Anderson Cancer Center
NCT05475171
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Georgetown University
NCT04865887
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06315257
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06677190
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
University Health Network, Toronto
NCT04016389
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Christian Hinrichs
NCT05483491
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
NCT06266338
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
UNC Lineberger Comprehensive Cancer Center
NCT04743674
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
Abramson Cancer Center at Penn Medicine
NCT05758688
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
University of California, San Diego
NCT07121543
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Christian Hinrichs
NCT05686226
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Yale University
NCT05838521
Detecting HPV DNA in Anal and Cervical Cancers
University of Chicago
NCT04857528
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Radiopharm Theranostics
NCT05799274
Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
The University of Texas Health Science Center, Houston
NCT06082882
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma
NCT04152499
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics
NCT05812027
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics
NCT05973487
Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)
H. Lee Moffitt Cancer Center and Research Institute
NCT05645146
Sexual Health Empowerment for Women's Health
University of Kansas Medical Center
NCT03984695
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
NCT05527184
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen, a wholly owned subsidiary of Pfizer
NCT03786081
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Agenus
NCT03894215
A Study of ADRX-0706 in Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT06036121
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05215574
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co.
NCT05438420
Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement
Baylor College of Medicine
NCT06577220
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Meghan Shea
NCT06238635
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Adlai Nortye Biopharma Co.
NCT04432857
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Cancer Institute (NCI)
NCT04708470
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Cancer Institute (NCI)
NCT04287868
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT02285192
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Cancer Institute (NCI)
NCT04432597
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Rutgers, The State University of New Jersey
NCT05220033
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03614949
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
M.D. Anderson Cancer Center
NCT05047913
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
M.D. Anderson Cancer Center
NCT05063916
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 30 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cervical Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cervical Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cervical Cancer page
151 registered trials, 73 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 73 Cervical Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Cervical Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cervical Cancer condition card totals 151 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.